# A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

> **NCT01376323** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 92 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK256073 1mg
- **DRUG:** GSK256073 5mg
- **DRUG:** GSK256073 10mg
- **DRUG:** GSK256073 25mg
- **DRUG:** Placebo
- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT01376323
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-13
- **Primary completion:** 2012-09-16
- **Final completion:** 2012-09-17
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376323, "A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01376323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*